STOCK TITAN
  1. Home
  2. Sec-filings
  3. FOCL
  4. [8-K] EDAP TMS SA Reports Material Event

FocalTherics (FOCL) posts 39% Q2 revenue growth and deeper net loss

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

FocalTherics (formerly EDAP TMS) reported second-quarter 2026 results for its continuing HIFU business, with total revenue of $13.2 million, up 39% from $9.5 million a year earlier. The company sold 13 Focal One systems versus 9 in 2025 and U.S. Focal One procedures grew 47% year-over-year.

Gross margin improved to 55.6% from 51.1%, driven by better standard costs and higher production volumes. Operating expenses rose to $15.4 million, including about $0.8 million of one-time rebranding, filer-transition, and discontinued-operations costs. Operating loss widened to $8.0 million, and net loss from continuing operations increased to $14.4 million, or ($0.39) per share, largely due to a $5.5 million loss from change in fair value of a warrant liability.

For the first half of 2026, continuing-operations revenue was $24.8 million with gross profit of $13.3 million. As of June 30, 2026, cash and cash equivalents were $21.5 million, long-term debt was $37.2 million, and shareholders’ equity was negative $3.2 million. The company reclassified its ESWL and Distribution segments as discontinued operations and reiterated 2026 guidance for its HIFU segment.

Positive

  • Revenue growth of 39% in Q2 2026 for the HIFU segment, to $13.2 million, with U.S. Focal One procedures up 47%, indicating strong demand and commercial traction.
  • Gross margin improved to 55.6% from 51.1% year-over-year, reflecting better standard costs for Focal One systems and favorable absorption from higher production volumes.
  • The company completed a strategic shift to focus on HIFU-based focal therapy, classifying ESWL and Distribution as discontinued operations and reiterating 2026 guidance for the HIFU segment.

Negative

  • Net loss more than doubled in Q2 2026 to $14.5 million from $6.4 million, or ($0.39) per share versus ($0.17), driven in part by warrant valuation impacts.
  • Shareholders’ equity turned negative to -$3.2 million at June 30, 2026, compared with positive $19.4 million at December 31, 2025, signaling balance sheet pressure.
  • Long-term debt rose sharply to $37.2 million from $15.9 million at year-end 2025, increasing leverage despite only modest cash growth to $21.5 million.
  • Operating loss from continuing operations widened to $8.0 million in Q2 2026 and $16.1 million for the first half, reflecting higher selling, general and administrative expenses.
Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Q2 2026 Revenue (HIFU) $13.2 million Total revenue from continuing operations in the quarter, up 39% from $9.5 million in 2025
Q2 2026 Gross Margin 55.6% Gross margin for continuing operations versus 51.1% in the prior-year quarter
Q2 2026 Net Loss $14.5 million Net loss including discontinued operations, compared with $6.4 million in Q2 2025
Q2 2026 Loss per Share ($0.39) Basic and diluted loss per share versus ($0.17) a year earlier
Cash and Cash Equivalents $21.5 million Cash and cash equivalents balance as of June 30, 2026
Long-Term Debt $37.2 million Non-current long-term debt as of June 30, 2026, up from $15.9 million at year-end 2025
Shareholders’ Equity -$3.2 million Total shareholders’ equity at June 30, 2026, versus $19.4 million at December 31, 2025
discontinued operations financial
"ESWL and Distribution segments met the criteria to be classified as discontinued operations"
Discontinued operations are parts of a company that it has decided to sell or shut down, and no longer plans to run in the future. This matters to investors because it helps them understand which parts of the business are ongoing and which are being phased out, providing a clearer picture of the company’s current performance and future prospects. Think of it like a store closing a department—it no longer contributes to sales or profits.
held for sale financial
"segments met the criteria to be classified as held for sale under ASC 205-20"
An asset or a group of assets classified as 'held for sale' is one the company intends to sell rather than keep using, and management has committed to that plan with an active effort to find a buyer. Investors care because these items are removed from ongoing operating results and valued differently, offering a clearer view of the business’s continuing performance—think of it like marking a piece of furniture for the garage sale rather than counting it as part of your regular household setup.
High-Intensity Focused Ultrasound (HIFU) medical
"This marks the Company's first reporting period presenting its HIFU business as continuing operations"
High-intensity focused ultrasound (HIFU) is a non-invasive medical treatment that uses focused sound waves to heat and destroy targeted tissue, much like using a magnifying glass to concentrate sunlight on a single spot. Investors watch HIFU because its safety profile, regulatory approvals, reimbursement rules and clinical results directly affect the market potential for devices and clinics offering the therapy, influencing revenue, competitive positioning and long-term growth prospects in medical technology.
warrant liability financial
"The increase in net loss was primarily attributable to the warrant valuation impact"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
operating cash flow financial
"OPERATING CASH FLOW was (11,820) for the six months ended June 30, 2026"
Operating cash flow is the amount of money a company earns from its main business activities, like selling products or services. It shows how well the company can generate cash to pay bills, invest in growth, or return money to shareholders. This figure helps investors understand if the company’s core operations are healthy and sustainable.
Q2 2026 Revenue (HIFU) $13.2 million vs. $9.5 million in Q2 2025 increase of 39%
Q2 2026 Gross Margin 55.6% vs. 51.1% in Q2 2025 improved margin
Q2 2026 Operating Loss $8.0 million vs. $6.6 million in Q2 2025 higher loss
Q2 2026 Net Loss $14.5 million vs. $6.4 million in Q2 2025 higher loss
Guidance

Reiterated 2026 guidance for continuing HIFU operations; specific figures not detailed.

FAQ

How did FocalTherics (FOCL) perform financially in Q2 2026?
FocalTherics reported Q2 2026 revenue of $13.2 million from continuing HIFU operations, up 39% year-over-year. However, net loss increased to $14.5 million, or ($0.39) per share, versus a $6.4 million loss, or ($0.17) per share, in Q2 2025.

What drove revenue growth for FocalTherics (FOCL) in Q2 2026?
Revenue growth was driven by 13 Focal One systems sold versus 9 a year earlier and a 47% increase in U.S. Focal One procedures. Total HIFU segment revenue rose 39% to $13.2 million, reflecting stronger commercial adoption of the company’s robotic HIFU platform.

Why did FocalTherics’ (FOCL) net loss increase despite higher revenue?
Net loss rose to $14.5 million despite higher revenue mainly due to a $5.5 million loss from change in fair value of a warrant liability and increased operating expenses. Q2 operating expenses reached $15.4 million, including about $0.8 million in one-time corporate costs.

What balance sheet changes did FocalTherics (FOCL) report as of June 30, 2026?
As of June 30, 2026, FocalTherics had $21.5 million in cash and cash equivalents and $37.2 million in long-term debt. Shareholders’ equity moved to negative $3.2 million, compared with positive $19.4 million at December 31, 2025, reflecting accumulated losses and higher liabilities.

How did FocalTherics (FOCL) change its segment reporting in 2026?
During Q2 2026, FocalTherics classified its ESWL and Distribution segments as discontinued operations after determining they were held for sale and part of a strategic shift. All continuing-operations figures now reflect only the company’s HIFU business, with prior periods recast on this basis.

Did FocalTherics (FOCL) provide any guidance for 2026?
The company reiterated its 2026 guidance for continuing HIFU operations in this report. Specific numerical guidance figures were not detailed in the text provided, but management emphasized continued focus on HIFU growth and expansion into additional indications such as endometriosis and BPH.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001041934 0001041934 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

_______________________________

 

FORM 8-K

_______________________________

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 13, 2026

_______________________________

 

EDAP TMS SA

(Exact name of registrant as specified in its charter) 

_______________________________

 

France 000-29374 98-1644844
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

 

Parc d’Activites la Poudrette-Lamartine
4/6, rue du Dauphiné
Vaulx-en-Velin, France 69120
(Address of Principal Executive Offices) (Zip Code)

 

(+33) 47-215-3150
(Registrant's telephone number, including area code)

 

(Former name or former address, if changed since last report)

_________________________________________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
American Depositary Shares, each representing one Ordinary Share (Ordinary Shares, nominal value €0.13 per share) FOCL NASDAQ Global Market

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

Item 2.02. Results of Operations and Financial Condition.

 

On August 13, 2026, EDAP TMS S.A. issued a press release and will hold a conference call regarding its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1   Press Release dated August 13, 2026
104   Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document

 

 

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 13, 2026 EDAP TMS S.A.
   
  /s/ Sanket Shah
  Sanket Shah
  General Counsel and Corporate Secretary

 

 

 

 

 

 

Exhibit 99.1 

FocalTherics™ Reports Second Quarter 2026 Financial Results

39% Revenue Increase and 47% Growth in U.S. Procedures

 

AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial results for the second quarter of 2026. This marks the Company's first reporting period presenting its HIFU business as continuing operations and its ESWL and Distribution businesses as discontinued operations.

 

Second Quarter 2026 Results and Recent Highlights of Continuing Operations (HIFU Segment)

 •Increased Revenue to $13.2 million, a 39% Increase Compared to the Prior Year Period
 •Delivered 47% U.S. Procedure Volume Growth over the Prior Year Period
 •Recorded 13 Focal One® Capital System Sales compared to 9 in the Prior Year Period, including 2 Conversions from Operating Leases
 •Expanded Focal One System Installed Base to 184, including 96 in the U.S. and 88 Internationally
 •Achieved 55.6% Gross Margin, Compared to 51.1% in the Prior Year Period
 •Completed Corporate Name Change to FocalTherics™
 •Launched First Commercial Focal One Endometriosis Program in Europe
 •Announced Underwritten Public Offering for $40 million of Gross Proceeds Expected to Close August 14, 2026

 

“We continue to demonstrate commercial success with our strongest second quarter ever, reflecting the growing strength of our core business and further supporting the strategic shift to Focal Therapy with our corporate rebranding to FocalTherics,” said Ryan Rhodes, CEO of FocalTherics. “Along with strong commercial momentum, we are also pleased with the developing progress of the endometriosis commercial launch in Europe and look forward to establishing additional Focal One programs to increase access to an important, non-surgical option for women with this highly debilitating condition. In addition, with expected proceeds from our ongoing capital raise, we will continue to accelerate commercial adoption in the global prostate cancer market while leveraging our multi-indication Focal One platform to grow market opportunities in treating endometriosis and expanding into benign prostatic hyperplasia or BPH. We will also continue to invest in our innovation and product development initiatives driving advances in AI-assisted treatments, FocalConnect™ telecollaboration technology, and integrating histotripsy together with HIFU on our Focal One platform.”

 

Second Quarter 2026 Financial Results for Continuing Operations (HIFU Segment)

Total revenue for the second quarter of 2026 was $13.2 million, compared to $9.5 million for the same period in 2025, representing an increase of 39% year-over-year. The Company sold thirteen Focal One systems during the quarter, versus nine systems in the same period in 2025, representing a year-over-year growth of 44%. The Company’s U.S. Focal One procedures grew 47% year-over-year.

Gross margin for the second quarter of 2026 was 55.6%, compared to 51.1% in the prior year period. The increase in gross margin was primarily attributable to improvement of the standard cost of the Focal One system and favorable absorption due to higher production volumes.

Operating expenses were $15.4 million for the second quarter of 2026, compared to $11.5 million in the prior year period. These expenses included approximately $0.8 million in one-time costs primarily attributable to corporate initiatives regarding rebranding, domestic filer transition and discontinued operations classification.

Operating loss was $8.0 million for the second quarter of 2026, compared to $6.6 million in the prior year period. Net loss was $14.4 million for the second quarter of 2026, or ($0.38) per share, compared to a net loss of $6.4 million, or ($0.17) per share in the prior year period. The increase in net loss was primarily attributable to the European Investment Bank warrant valuation impact of $5.5 million during the quarter.

 

 

Cash and cash equivalents as of June 30, 2026 totaled $21.5 million.

Reiterating 2026 Guidance for Continuing Operations (HIFU Segment)

 •Total revenue of $50.0 - $54.0 million, representing 34% - 45% year-over-year growth

 

Discontinued Operations

During the second quarter of 2026, the ESWL and Distribution segments met the criteria to be classified as held for sale under ASC 205-20, Presentation of Financial Statements — Discontinued Operations, and ASC 360-10, Property, Plant, and Equipment, and the Company determined that the planned exit represents a strategic shift that will have a significant effect on the Company’s operations and financial results. Accordingly, the Company’s unaudited financial results as of and for the three and six months ended June 30, 2026 reflect the Company’s ESWL and Distribution operating segments as discontinued operations.

Prior-period results presented in this release have been recast to reflect this classification on a consistent basis. As a result, all continuing operations figures and growth rates presented herein reflect the Company's HIFU business only.

Conference Call Information

A conference call and webcast to discuss the second quarter 2026 financial results will be hosted by Ryan Rhodes, Chief Executive Officer and Ken Mobeck, Chief Financial Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Date: 

Thursday, August 13, 2026, at 4:30 p.m. Eastern Time

Domestic: 

1-800-245-3047

International: 

1-203-518-9765

Passcode: 

FOCAL 

Webcast: 

https://viavid.webcasts.com/starthere.jsp?ei=1767672&tp_key=2d69d92ca7

 

About FocalTherics
A recognized global leader in robotic focal therapy, FocalTherics develops, manufactures, and markets minimally invasive medical devices worldwide to treat various conditions using proprietary focused ultrasound technology. The Company’s flagship platform, Focal One Robotic HIFU, combines advanced imaging, real-time treatment planning, robotic precision, and HIFU technology to deliver personalized focal therapy designed to optimize clinical outcomes while preserving quality of life.

 

Forward-Looking Statements

 

In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved, and include statements such as quote from our Chief Executive Officer, the expected closing and proceeds from our offering, and our financial performance guidance. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.

 

 

 

Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

 

Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.

 

Investor Contact

Louisa Smith

Gilmartin Group

investor.relations@focalone.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Amounts in thousands of U.S. Dollars, except per share data)

 

       
   Three Months Ended:
   June 30,  June 30,
   2026  2025
   $US  $US
Sales of goods   9,527    6,385 
Sales of RPPs & leases   2,758    2,155 
Sales of spare parts and services   918    969 
TOTAL NET SALES   13,203    9,509 
Other revenues   (0)   - 
TOTAL REVENUES   13,203    9,509 
Cost of sales   (5,865)   (4,646)
GROSS PROFIT   7,338    4,863 
Research & development expenses   (2,317)   (2,291)
Selling, general & administrative expenses   (13,054)   (9,194)
Total operating expenses   (15,371)   (11,485)
LOSS FROM OPERATIONS   (8,033)   (6,623)
Interest (expense) income, net   (748)   (79)
Loss from change in fair value of warrant liability   (5,547)   - 
Currency exchange gains (loss), net   (76)   362 
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS   (14,404)   (6,340)
Income tax (expense) credit, net from continuing operations   (8)   (14)
LOSS FROM CONTINUING OPERATIONS   (14,412)   (6,354)
Income(loss) from discontinued operations, net of tax   (75)   (51)
NET LOSS   (14,487)   (6,406)
Loss per share – Basic and diluted   (0.39)   (0.17)
Average number of shares used in computation of EPS - basic and dilutive   37,527,950    37,420,318 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands of U.S. Dollars, except per share data)

       
   Six Months Ended:
   June 30,  June 30,
   2026  2025
   $US  $US
Sales of goods   17,782    10,185 
Sales of RPPs & leases   5,250    4,100 
Sales of spare parts and services   1,764    1,724 
TOTAL REVENUES   24,796    16,009 
Cost of sales   (11,496)   (7,989)
GROSS PROFIT   13,300    8,020 
Research & development expenses   (4,784)   (4,648)
Selling, general & administrative expenses   (24,574)   (16,739)
Total operating expenses   (29,357)   (21,388)
LOSS FROM OPERATIONS   (16,057)   (13,368)
Interest (expense) income, net   (1,151)   (81)
Loss from change in fair value of warrant liability   (6,851)   - 
Currency exchange gains (loss), net   77    (664)
LOSS BEFORE TAXES FROM CONTINUING OPERATIONS   (23,982)   (14,113)
Income tax (expense) credit, net from continuing operations   (25)   (23)
LOSS FROM CONTINUING OPERATIONS   (24,007)   (14,135)
Income(loss) from discontinued operations, net of tax   437    285 
NET LOSS   (23,570)   (13,850)
Loss per share – Basic and diluted   (0.63)   (0.37)
Average number of shares used in computation of EPS - basic and dilutive   37,481,986    37,406,202 

 

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands of U.S. Dollars)

       
   June 30,  December 31,
   2026  2025
   $US  $US
Cash, cash equivalents   21,542    20,452 
Accounts receivable, net   10,060    14,948 
Inventory   8,251    7,770 
Other current assets   2,350    2,439 
Total current assets of discontinued operations   16,812    11,555 
TOTAL CURRENT ASSETS   59,015    57,164 
Property, plant and equipment, net   8,635    8,789 
Goodwill   735    757 
Other non-current assets   6,164    6,181 
Total non-current assets of discontinued operations   -    6,106 
TOTAL ASSETS   74,548    78,997 
Accounts payable & other accrued liabilities   17,830    17,436 
Deferred revenues, current portion   6,395    6,452 
Short term borrowing   1,860    4,386 
Other current liabilities   1,786    3,005 
Total current liabilities of discontinued operations   8,978    5,862 
TOTAL CURRENT LIABILITIES   36,849    37,141 
Obligations under operating and finance leases non-current   835    1,183 
Long-term debt, non-current   37,197    15,903 
Deferred revenues, non-current   923    768 
Other long-term liabilities   1,970    1,632 
Total non-current liabilities of discontinued operations   -    2,957 
TOTAL LIABILITIES   77,773    59,584 
TOTAL SHAREHOLDERS’EQUITY   (3,225)   19,413 
TOTAL LIABILITIES & SHAREHOLDERS’ EQUITY   74,548    78,997 

 

EDAP TMS S.A.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Amounts in thousands of U.S. Dollars)

       
   Six Months Ended  Six Months Ended
   June 30,  June 30,
   2026  2025
   ($US)  ($US)
NET INCOME (LOSS)   (23,570)   (13,850)

Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities(1)

   11,750    3,024 
OPERATING CASH FLOW   (11,820)   (10,827)
Increase/Decrease in operating assets and liabilities   5,157    779 
NET CASH GENERATED BY (USED IN) OPERATING ACTIVITIES   (6,663)   (10,047)
Short term investments   -    - 
Additions to capitalized assets produced by the company and other capital expenditures   (2,017)   (2,917)
NET CASH GENERATED BY (USED IN) INVESTING ACTIVITIES   (2,017)   (2,917)
NET CASH GENERATED BY (USED IN) FINANCING ACTIVITIES   10,402    (1,198)
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS   (632)   2,231 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   1,090    (11,931)

 

(1) including share-based compensation expenses for $1,157,000 for the six months ended June 30, 2026 and $847,000 for the six months ended June 30, 2025, as well as warrant fair value adjustment of $4,847,000 related to Tranche A and $1,597,000 related to Tranche B for the six months ended June 30, 2026

 

 

EDAP TMS S.A.

UNAUDITED CONDENSED STATEMENTS OF OPERATIONS BY DIVISION

six months ended June 30, 2026

(Amounts in thousands of U.S. Dollars)

                
Six months ended  HIFU     Reconciling  Total After   
June 30, 2026  Division     Items  Consolidation   
Sales of goods   17,782         -    17,782      
Sales of RPPs & leases   5,250         -    5,250      
Sales of spare parts and services   1,764         -    1,764      
TOTAL REVENUES   24,796         -    24,796      
GROSS PROFIT (% of Net Sales)   13,300    53.6%   -    13,300    53.6%
Research & development expenses   (4,784)        -    (4,784)     
Selling, general & administrative expenses   (20,309)        (4,265)   (24,574)     
OPERATING PROFIT (LOSS)   (11,792)        (4,265)   (16,057)     

 

 

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents